It seemed a long time ahead when Nolan signed up for it but, after several months of getting up at 5am to train, his cycle ride from Land’s End to John O’Groats is only four
Seth Coffelt, who leads the team at the Beatson Institute for Cancer Research at the University of Glasgow which has received funding for the past three years through the generosity of Secondary1st fundraisers and donors,
In 2020 in the middle of the pandemic Angela, who had been diagnosed with secondary breast cancer the previous year, completed the 2.6 challenge by walking for 26 miles on her old cross trainer. Two
Just three weeks after finishing in the Brighton Marathon Superhero Tim completed the London Marathon. Marathons, skydiving, fitness challenges… there seems no end to the adventures Tim undertakes to raise money for Secondary1st. He is
A team of scientists at King’s College London has developed an Artificial Intelligence model which analyses immune responses in the lymph nodes to predict the likelihood of developing secondary breast cancer for patients with triple
Last year Nolan rode a zipwire to raise money for Secondary1st. This year he’s planning to undertake a more down to earth challenge. In September he will cycle more than 1000 km, riding all the
Not content with skydiving, running a marathon and organizing a fitness challenge to raise money for Secondary1st our superhero Tim ran in the Brighton Marathon and then after a gap of only three weeks he’s going
In June 2022 we reported that favourable results from a trial of a new cancer drug, Enhertu (trastuzumab deruxtecan), had been presented at this year’s meeting of the American Society of Clinical Oncology and had
Dr Coffelt and his team at the Beatson Institute for Cancer Research in Glasgow in another project funded by Secondary1st’s fundraisers and donors are working to understand why existing immunotherapies are less effective in treating
At the University of Bradford in one of the projects funded by the wonderful donors and fundraisers of Secondary1st Professor Pors and his PhD student Enrica are continuing their work to improve duocarmycins, a very